B-cell Lymphoid Malignancies
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
EscugenESG206
EscugenESG206
Clinical Trials (2)
Total enrollment: 13 patients across 2 trials
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Start: Dec 2025Est. completion: Dec 20260
Phase 1Withdrawn
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
Start: Aug 2023Est. completion: Jan 202513 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.